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weet and Sticky
iabetic Platelets, Enhanced Reactivity,
nd Cardiovascular Risk*
aniel I. Simon, MD, FACC,†
lvin H. Schmaier, MD‡
leveland, Ohio
latelets play a pivotal role in the pathogenesis of acute
oronary syndromes and in the thrombotic complications
fter percutaneous coronary intervention. Oral antiplatelet
gents are the cornerstone of pharmacological therapy for
reventing major adverse cardiovascular events. Aspirin and
hienopyridine derivatives (ticlopidine, clopidogrel), by
locking thromboxane A2 formation and the adenosine
iphosphate (ADP) receptor P2Y12 platelet activation path-
ays, respectively, are the major oral antiplatelet drugs in
linical practice. The Swedish angina pectoris aspirin trial,
n which 2,035 patients were allocated to receive 75 mg of
spirin daily or placebo (1), showed that aspirin therapy led
o significant reductions in death and myocardial infarction
mong patients with unstable angina (46% reduction), those
ndergoing coronary angioplasty (53% reduction), and
hose with stable angina (33% reduction). When given in
ombination with aspirin, thienopyridines inhibit platelet
ggregation to a greater extent than either agent alone (2).
See page 1541
everal studies have demonstrated a dramatic, nearly 5-fold
eduction in acute and subacute stent thrombosis when
spirin in combination with a thienopyridine was used after
tenting compared with either aspirin alone or aspirin plus
arfarin (3,4). In the setting of acute coronary syndromes,
ombination therapy with aspirin and clopidogrel signifi-
antly reduce ischemic complications compared to aspirin
lone (9.3% vs. 11.4%, relative risk reduction 20%, p 
.001) (5). The benefit with clopidogrel was noted early
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eceives research funding from Accumetrics.within 24 h of treatment), was sustained at 1 year, and
bserved in all patients with acute coronary syndromes
egardless of their level of risk or treatment strategy (i.e.,
edical therapy, percutaneous coronary intervention, or
oronary artery bypass grafting).
Variability in the response to antiplatelet drugs has been
ecognized for decades. Antiplatelet drug resistance or
nonresponsiveness” is used to describe the clinical obser-
ation of the inability of the antiplatelet agent to prevent
hrombotic vascular events or the laboratory phenomenon of
educed effect of the antiplatelet agent on one or more tests
f platelet function. The mechanisms of aspirin and clopi-
ogrel nonresponsiveness are incompletely defined. In the
ase of aspirin, multiple cellular, clinical, and genetic factors
ikely contribute to variable responses among individuals
hen given a fixed dose of aspirin (6). For clopidogrel, the
etabolic activity of hepatic P450 3A4 is largely responsible
or converting clopidogrel to its active thiol metabolite that
inds to and inhibits the P2Y12 ADP receptor. Increasing
lopidogrel dose or hepatic P450 3A4 activity enhances the
latelet inhibitory response of clopidogrel (7).
There is a growing amount of evidence demonstrating
hat hypo- or nonresponsiveness to antiplatelet drugs in ex
ivo testing is associated with adverse clinical events in
iverse patient populations with atherosclerotic disease in
oth stable and unstable phases as well as in the postper-
utaneous coronary and peripheral intervention settings (8).
or example, clopidogrel nonresponsiveness is associated
ith adverse cardiovascular outcomes after elective (9) and
mergency (10) percutaneous coronary intervention. En-
anced platelet reactivity also has been observed in patients
ith postpercutaneous coronary intervention treated with
spirin and clopidogrel who go on to develop stent throm-
osis compared with those who remain free of stent throm-
osis (63.28  9.56% vs. 39.80  10.9%, p  0.001) (11).
In this issue of the Journal, Angiolillo et al. (12) provide
dditional evidence for the potential importance of variable
ntiplatelet responsiveness by showing that residual high
latelet reactivity (HPR) in a subset of diabetic patients with
oronary artery disease on dual antiplatelet therapy is
ssociated with increased risk of major adverse cardiovascu-
ar events. Platelet light transmission aggregometry (LTA)
nd flow cytometry for expression of epitopes indicating
revious thrombocyte activation were assessed in type 2
iabetes mellitus patients (n  173) who had previously
ndergone percutaneous coronary intervention and were on
hronic treatment with aspirin (100 mg daily) and clopi-
ogrel (75 mg daily). Platelet reactivity was determined
sing 20 M ADP-induced platelet aggregation and di-
ided into quartiles. The upper quartile (Aggmax 62%)
efined HPR. The strongest independent predictor of major
dverse cardiovascular events was HPR with a hazard ratio
f 3.35 (95% confidence interval 1.68 to 6.66, p  0.001).
nterestingly, patients with HPR to ADP tended to have
PR to multiple additional agonists, including collagen,
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tudy contrasts with others in diabetics where no signif-
cant differences in platelet aggregation responses were
oted (13,14). The distinguishing feature of the Angio-
illo et al. (12) study is that these investigators stratified
heir diabetic patient population into quartiles of ADP-
nduced platelet responsiveness to recognize that the
ubgroup with the least inhibited platelets have higher
isk for adverse events.
High post-treatment platelet reactivity is also an impor-
ant predictor of 30-day clinical outcomes in patients with
cute coronary syndromes undergoing coronary stenting
15). Cuisset et al. (15) randomized patients to 300- or
00-mg loading dose of clopidogrel at least 12 h before
ercutaneous coronary intervention. Immediately before
tenting, ADP-induced platelet aggregation was performed
n a single post-treatment blood sample, and HPR was
efined as Aggmax 70%. They found that HPR was less
ommon in patients receiving 600 mg rather than 300 mg of
lopidogrel (15% vs. 25%, p  0.03). In a multivariable
ogistic regression analysis that included both clopidogrel
oading doses, HPR, and several cardiovascular risk factors
nd inflammatory parameters, only HPR remained inde-
endently associated with cardiovascular events (hazard
atio  13.82; 95% confidence interval 5.30 to 36.04, p 
.0001).
Although LTA is used widely to detect classic platelet
unction disorders, its usefulness in identifying HPR in
atient populations is not universally accepted. Healthy
ndividuals (n  359) exhibit considerable interindividual
ariability in aggregation responses (16). For example, the
threshold” concentration of ADP- or epinephrine-induced
econd wave aggregation and granule secretion in normal
latelets varies from 1 to 7.5 M and 0.5 to 10 M,
espectively (17). Further, for each agonist tested at sub-
aximal concentrations, a small proportion of individuals
emonstrate unusually robust aggregation responses (16). In
ee et al. (16), epinephrine and collagen related-peptide
gonists were the most reliable and efficient in detecting
yper-reactivity, and in an important substudy, the authors
ote that epinephrine hyper-reactivity persists for up to 3
ears. These authors proposed that classification of HPR be
estricted to individuals who demonstrate 60% aggrega-
ion to 0.4 M epinephrine or 50% aggregation to 0.005
g/ml collagen-related peptide on at least 2 occasions (18).
t is important to note that only now standard approaches to
erform platelet aggregation studies are being proposed;
hus, it may be necessary to develop a broader definition of
hat constitutes HPR (17,19). Presently, each institution
eeds to develop its own measure of normal and determine
ho in a patient population is characterized in the most
eactive quartile.
Marked differences in platelet reactivity between healthy
ndividuals and between patients with cardiovascular disease
aise important questions about their molecular determi-
ants. Both Angiolillo et al. (12) and Yee et al. (16) eemonstrated that individuals who demonstrate hyper-
eactivity to one agonist tended to show a similar response
o other agonists, indicative of a global hyperactive platelet
tatus. This observation suggests that HPR result from
ommon downstream signaling events involving g-proteins,
alcium transients, kinases/phosphatases, and phosphodies-
erases that can be influenced by genetic and/or other
onditions.
The present study of Angiolillo et al. (12) also has
mportant implications for the understanding and preven-
ion of recurrent cardiovascular events in diabetic patients.
iabetes mellitus markedly increases the risk of myocardial
nfarction, stoke, amputation, and death (20). The abnormal
etabolic state that accompanies diabetes alters the func-
ion of multiple cell types, including endothelial cells and
latelets. Chronic hyperglycemia, insulin resistance, and
yperlipidemia promote endothelial dysfunction and also
nhance platelet reactivity and thrombosis. The mechanism
y which diabetes enhances platelet function is multifactoral
21). Platelets from diabetics have activation of protein
inase C (22), elevated adenine nucleotides (23), increased
latelet Fc receptor expression (24), greater levels of phos-
horylated Syk (24), and more sensitivity to ADP (25).
iabetic platelets also have decreased production of
latelet-derived, as well as endothelial-derived nitric oxide,
hich inhibits platelet adhesion and aggregation, and in-
reased formation of O2
 (22), which further diminishes
he bioavailability of nitric oxide by forming peroxynitrite
ONOO). Production of peroxynitrite also impairs the
roduction of endothelial-derived prostacyclin, which has
mportant antiadhesive and antiaggregatory actions on
latelets (26). Finally, obesity is central to the pathogenesis
f type 2 diabetes mellitus, and its influence on leptin
odulates platelet function. Platelets express the leptin
eceptor, and leptin potentates the aggregation of platelets
n response to multiple agonists, including ADP (27).
eptin-deficient and leptin receptor-deficient mice have
mpaired thrombus formation in vivo, indicating that leptin
as an essential role in hemostasis (27,28). Diabetics also
ave elevated adiponectin levels in association with in-
reased basal platelet reactivity (29).
Management of diabetic patients with platelet hyperac-
ivity is uncertain. Increasing the clopidogrel dose may be
nsufficient to eliminate hyperactivity because suboptimal
lopidogrel response was still present in 60% of diabetic
atients on the 150-mg rather than 75-mg clopidogrel
egimen in the randomized OPTIMUS study (Optimizing
ntiplatelet therapy in Diabetes Mellitus) (30). The obser-
ations of Angiolillo et al. (12) and Yee et al, (16) indicate
hat there is a subset of individuals with and without
iabetes with HPR who may require combinations of new
ntiplatelet agents (e.g., second-generation P2Y12 inhibi-
ors, thrombin receptor antagonists, glycoprotein VI inhib-
tors) in addition to aspirin and clopidogrel to optimize
latelet “anesthesia” and ameliorate risk for cardiovascular
vents.
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